Effect of transmitted drug resistance on virological and immunological response to initial combination antiretroviral therapy for HIV (EuroCoord-CHAIN joint project): a European multicohort study.

BACKGROUND The effect of transmitted drug resistance (TDR) on first-line combination antiretroviral therapy (cART) for HIV-1 needs further study to inform choice of optimum drug regimens. We investigated the effect of TDR on outcome in the first year of cART within a large European collaboration. METHODS HIV-infected patients of any age were included if they started cART (at least three antiretroviral drugs) for the first time after Jan 1, 1998, and were antiretroviral naive and had at least one sample for a genotypic test taken before the start of cART. We used the WHO drug resistance list and the Stanford algorithm to classify patients into three resistance categories: no TDR, at least one mutation and fully-active cART, or at least one mutation and resistant to at least one prescribed drug. Virological failure was defined as time to the first of two consecutive viral load measurements over 500 copies per mL after 6 months of therapy. FINDINGS Of 10,056 patients from 25 cohorts, 9102 (90·5%) had HIV without TDR, 475 (4·7%) had at least one mutation but received fully-active cART, and 479 (4·8%) had at least one mutation and resistance to at least one drug. Cumulative Kaplan-Meier estimates for virological failure at 12 months were 4·2% (95% CI 3·8-4·7) for patients in the no TDR group, 4·7% (2·9-7·5) for those in the TDR and fully-active cART group, and 15·1% (11·9-19·0) for those in the TDR and resistant group (log-rank p<0·0001). The hazard ratio for the difference in virological failure between patients with TDR and resistance to at least one drug and those without TDR was 3·13 (95% CI 2·33-4·20, p<0·0001). The hazard ratio for the difference between patients with TDR receiving fully-active cART and patients without TDR was 1·47 (95% CI 0·19-2·38, p=0·12). In stratified analysis, the hazard ratio for the risk of virological failure in patients with TDR who received fully-active cART that included a non-nucleoside reverse transcriptase inhibitor (NNRTI) compared with those without TDR was 2·0 (95% CI 0·9-4·7, p=0·093). INTERPRETATION These findings confirm present treatment guidelines for HIV, which state that the initial treatment choice should be based on resistance testing in treatment-naive patients. FUNDING European Community's Seventh Framework Programme FP7/2007-2013 and Gilead.

[1]  R. Kaiser,et al.  Primary HIV Drug Resistance and Efficacy of First-Line Antiretroviral Therapy Guided by Resistance Testing , 2006, Journal of acquired immune deficiency syndromes.

[2]  Amalio Telenti,et al.  Antiretroviral Treatment of Adult HIV Infection2010 Recommendations of the International AIDS Society–USA Panel , 2010 .

[3]  H. Jessen,et al.  Prevalence of Transmitted Drug Resistance and Impact of Transmitted Resistance on Treatment Success in the German HIV-1 Seroconverter Cohort , 2010, PloS one.

[4]  H. Jessen,et al.  Impact of transmission of drug‐resistant HIV on the course of infection and the treatment success. Data from the German HIV‐1 Seroconverter Study , 2007, HIV medicine.

[5]  D. Pillay,et al.  The impact of transmitted drug resistance on the natural history of HIV infection and response to first-line therapy , 2006, AIDS.

[6]  B. Ledergerber,et al.  HIV Cohort Collaborations: Proposal for Harmonization of Data Exchange , 2004, Antiviral therapy.

[7]  B. Gazzard,et al.  The Impact of Transmitted Drug-Resistance on Treatment Selection and Outcome of First-Line Highly Active Antiretroviral Therapy (HAART) , 2009, Journal of acquired immune deficiency syndromes.

[8]  W. Heneine,et al.  Prevalence of transmitted drug resistance associated mutations and HIV-1 subtypes in new HIV-1 diagnoses, U.S.–2006 , 2010, AIDS.

[9]  Douglas D. Richman,et al.  Antiretroviral Treatment of Adult HIV Infection , 2008 .

[10]  F. Brun-Vézinet,et al.  Response to HAART in French patients with resistant HIV-1 treated at primary infection: ANRS Resistance Network , 2007, Antiviral therapy.

[11]  S. Hammer,et al.  Antiretroviral therapy for HIV infection in 1998: updated recommendations of the International AIDS Society-USA Panel. , 1997, JAMA.

[12]  Rodolphe Thiébaut,et al.  Transmission of HIV-1 minority-resistant variants and response to first-line antiretroviral therapy , 2008, AIDS.

[13]  K. Metzner,et al.  Efficient suppression of minority drug-resistant HIV type 1 (HIV-1) variants present at primary HIV-1 infection by ritonavir-boosted protease inhibitor-containing antiretroviral therapy. , 2010, The Journal of infectious diseases.

[14]  B. Gazzard.  British HIV Association guidelines for the treatment of HIV‐1‐infected adults with antiretroviral therapy 2008 , 2005, HIV medicine.

[15]  J. Church,et al.  ANTIRETROVIRAL-DRUG RESISTANCE AMONG PATIENTS RECENTLY INFECTED WITH HIV , 2003, Pediatrics.

[16]  A. Mocroft,et al.  Transmitted Drug Resistant HIV-1 and Association With Virologic and CD4 Cell Count Response to Combination Antiretroviral Therapy in the EuroSIDA Study , 2008, Journal of acquired immune deficiency syndromes.

[17]  Roger Paredes,et al.  Pre-existing minority drug-resistant HIV-1 variants, adherence, and risk of antiretroviral treatment failure. , 2010, The Journal of infectious diseases.

[18]  A. Geretti,et al.  Prevalence and determinants of transmitted antiretroviral drug resistance in HIV-1 infection. , 2007, The Journal of antimicrobial chemotherapy.

[19]  A. d’Arminio Monforte,et al.  Response to combination antiretroviral therapy: variation by age , 2008, AIDS.

[20]  Marco Mancini,et al.  Prevalence and Clinical Significance of HIV Drug Resistance Mutations by Ultra-Deep Sequencing in Antiretroviral-Naïve Subjects in the CASTLE Study , 2010, PloS one.

[21]  Tommy F. Liu,et al.  Web resources for HIV type 1 genotypic-resistance test interpretation. , 2006, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[22]  S. Hammer,et al.  Low frequency nonnucleoside reverse-transcriptase inhibitor-resistant variants contribute to failure of efavirenz-containing regimens in treatment- experienced patients. , 2010, The Journal of infectious diseases.

[23]  Anne-Mieke Vandamme,et al.  Drug Resistance Mutations for Surveillance of Transmitted HIV-1 Drug-Resistance: 2009 Update , 2009, PloS one.

[24]  Tulio de Oliveira,et al.  An automated genotyping system for analysis of HIV-1 and other microbial sequences , 2005, Bioinform..

[25]  Matthias Cavassini,et al.  Minority quasispecies of drug-resistant HIV-1 that lead to early therapy failure in treatment-naive and -adherent patients. , 2009, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[26]  angesichts der Corona-Pandemie,et al.  UPDATE , 1973, The Lancet.

[27]  Jörg Schüpbach,et al.  Transmission of HIV-1 drug resistance in Switzerland: a 10-year molecular epidemiology survey , 2007, AIDS.

[28]  M. Poljak,et al.  Transmission of drug-resistant HIV-1 is stabilizing in Europe. , 2009, The Journal of infectious diseases.

[29]  Christine Hogan,et al.  Tracking the Prevalence of Transmitted Antiretroviral Drug-Resistant HIV-1: A Decade of Experience , 2006, Journal of acquired immune deficiency syndromes.

[30]  A. Telenti,et al.  Emergence of HIV-1 drug resistance in previously untreated patients initiating combination antiretroviral treatment: a comparison of different regimen types. , 2007, Archives of internal medicine.

[31]  Michael Monsour,et al.  Minority HIV-1 Drug Resistance Mutations Are Present in Antiretroviral Treatment–Naïve Populations and Associate with Reduced Treatment Efficacy , 2008, PLoS medicine.

[32]  Gregory S Turenchalk,et al.  Low-abundance drug-resistant viral variants in chronically HIV-infected, antiretroviral treatment-naive patients significantly impact treatment outcomes. , 2009, The Journal of infectious diseases.

[33]  Edward P Acosta,et al.  Preexisting resistance to nonnucleoside reverse-transcriptase inhibitors predicts virologic failure of an efavirenz-based regimen in treatment-naive HIV-1-infected subjects. , 2008, The Journal of infectious diseases.